DMAC icon

DiaMedica Therapeutics

4.18 USD
+0.25
6.36%
At close Jul 18, 4:00 PM EDT
After hours
4.38
+0.20
4.78%
1 day
6.36%
5 days
14.84%
1 month
9.42%
3 months
18.41%
6 months
-27.93%
Year to date
-24.14%
1 year
28.22%
5 years
-35.99%
10 years
34.84%
 

About: DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Employees: 28

0
Funds holding %
of 7,321 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

600% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 2

533% more call options, than puts

Call options by funds: $57K | Put options by funds: $9K

100% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 10

27% more funds holding

Funds holding: 45 [Q4 2024] → 57 (+12) [Q1 2025]

1.8% more ownership

Funds ownership: 15.74% [Q4 2024] → 17.53% (+1.8%) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]

22% less capital invested

Capital invested by funds: $36.5M [Q4 2024] → $28.5M (-$8.06M) [Q1 2025]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$11
163%
upside
Avg. target
$12.33
195%
upside
High target
$14
235%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
Craig-Hallum
Chase Knickerbocker
163%upside
$11
Buy
Maintained
18 Jul 2025
Lake Street
Thomas Flaten
235%upside
$14
Buy
Maintained
18 Jul 2025
HC Wainwright & Co.
Matthew Caufield
187%upside
$12
Buy
Maintained
18 Jul 2025

Financial journalist opinion

Neutral
Business Wire
2 days ago
DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, today announced positive interim results from Part 1a of the Phase 2 study of DM199 for the treatment of preeclampsia. The study achieved pre-specified safety and efficacy endpoints for the Part 1a dose escalation phase, reinforcing the therapeutic potential of DM199. DM199, rinvecalinase alfa, is a recombinant form of the KLK1 protein expected to influence blood pressure regula.
DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer
Neutral
Business Wire
3 weeks ago
DiaMedica Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, today announced its upcoming addition as a member of the US small-cap Russell 2000 and Russell 3000 Indexes, effective after the U.S. market closes on June 27. The Russell 3000 Index encompasses the 3,000 largest U.S. companies by market capitalization, representing approximately 98% of the investa.
DiaMedica Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes
Neutral
Business Wire
1 month ago
DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, today announced that Rick Pauls, President and CEO, and Dave Wambeke, Chief Business Officer, will present at the upcoming Jefferies Global Healthcare Conference, being held in New York City, NY, June 3 – 5, 2025. Management will be available for one-on-one meetings with investors to discuss the co.
DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025
Neutral
Business Wire
2 months ago
DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing a novel treatment for preeclampsia, announced today that it will host a virtual key opinion leader (KOL) event on Wednesday, May 28, 2025, at 8:00 AM ET to provide further insight into the current treatment landscape of preeclampsia and the clinical trial design and endpoints of the DM199 Phase 2 preeclampsia study. The webinar will feature Prof. Stephen Ton.
DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia
Neutral
Business Wire
2 months ago
DiaMedica Therapeutics Announces Poster Presentation at European Stroke Organisation Conference – ESOC 2025
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today a poster presentation of the safety and clinical outcomes for ReMEDy2 study, the planned pivotal phase 2/3 trial of DM199 in AIS patients, at the 11th European Stroke Organisation Conference – ESOC 2025 being held in Helsinki, Finland from May 21-23, 2025. For information about the event, visit:.
DiaMedica Therapeutics Announces Poster Presentation at European Stroke Organisation Conference – ESOC 2025
Neutral
Seeking Alpha
2 months ago
DiaMedica Therapeutics Inc. (DMAC) Q1 2025 Earnings Call Transcript
DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q1 2025 Earnings Conference Call May 14, 2025 8:00 AM ET Company Participants Rick Pauls - President and Chief Executive Officer Scott Kellen - Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Matthew Caufield - H.C. Wainwright Chase Knickerbocker - Craig-Hallum Operator Good morning ladies and gentlemen, and welcome to the DiaMedica Therapeutics First Quarter 2025 Conference Call.
DiaMedica Therapeutics Inc. (DMAC) Q1 2025 Earnings Call Transcript
Neutral
Business Wire
2 months ago
DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke and preeclampsia, today provided a business update and financial results for the quarter ended March 31, 2025. Management will host a conference call Wednesday, May 14, 2025, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and first quarter 2025 financial results. Preeclampsia Phase 2 C.
DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights
Neutral
Business Wire
2 months ago
DiaMedica Therapeutics to Participate in Upcoming Investor Conferences in May
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that the Company will participate in upcoming investor conferences in May 2025. 2025 RBC Capital Markets Global Healthcare Conference Tuesday, May 20th – Wednesday, May 21st, 2025, in New York City, New York. Management will be available for one-on-one meetings throughout the conference. H.C. Wai.
DiaMedica Therapeutics to Participate in Upcoming Investor Conferences in May
Neutral
Business Wire
2 months ago
DiaMedica Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update May 14, 2025
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, announced today that its first quarter 2025 financial results will be released after the markets close on Tuesday, May 13th. DiaMedica will host a live conference call on Wednesday, May 14th at 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details:.
DiaMedica Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update May 14, 2025
Neutral
Seeking Alpha
4 months ago
DiaMedica Therapeutics Inc. (DMAC) Q4 2024 Earnings Call Transcript
DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q4 2024 Earnings Conference Call March 18, 2025 8:00 AM ET Company Participants Rick Pauls - President and CEO Lorianne Masuoka - CMO Scott Kellen - CFO Conference Call Participants Thomas Flaten - Lake Street Chase Knickerbocker - Craig-Hallum Matthew Caufield - H.C. Wainwright Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Full Year 2024 Conference Call.
DiaMedica Therapeutics Inc. (DMAC) Q4 2024 Earnings Call Transcript
Charts implemented using Lightweight Charts™